Barrett’s esophagus, reflux esophagitis, and eosinophilic esophagitis

 

 Buy Article Permissions and Reprints

Many new and exciting endoscopy-related studies on Barrett’s esophagus, reflux esophagitis, and eosinophilic esophagitis were presented during the 2012 Digestive Disease Week (DDW; 19 – 22 May, San Diego, California, USA). Endoscopic research in Barrett’s esophagus mainly focused on surveillance, detection, and ablation therapy, while clinical studies in eosinophilic esophagitis concerned budesonide treatment and dietary measures, and those on reflux esophagitis covered various issues related to anti-reflux surgery. In this review, we discuss our top 20 DDW 2012 abstracts on these three topics.

• References

• 1 Bulsiewicz WJ, Infantolino A, Ertan A et al. Length of Barrett’s esophagus predicts likelihood of complete eradication of intestinal metaplasia and number of treatment sessions of radiofrequency ablation (RFA): results From the U.S. RFA Registry. Gastrointest Endosc 2012; 75: AB121
  PubMedGoogle Scholar
• 2 Bulsiewicz WJ, Lightdale CJ, Pruitt RE et al. Predictors of complete eradication of Barrett’s esophagus by radiofrequency ablation (RFA) in a nationwide, multicenter cohort: results from the U.S. RFA Registry. Gastroenterology 2012; 142: 3-4
  PubMedGoogle Scholar
• 3 van Vilsteren FG, Alvarez Herrero L, Pouw RE et al. A multicenter randomized trial comparing two ablation regimens for focal radiofrequency ablation of Barrett’s mucosa using the HALO₉₀ system. Gastroenterology 2012; 142: 1038
  CrossrefPubMedGoogle Scholar
• 4 Shaheen NJ, Bulsiewicz WJ, Lyday WD et al. Prior fundoplication does not improve subsequent safety or efficacy outcomes of radiofrequency ablation (RFA): results From the U.S. RFA Registry. Gastroenterology 2012; 142: 1040-1041
  PubMedGoogle Scholar
• 5 Gupta M, Lutzke LS, Prasad GA et al. Recurrence of intestinal metaplasia after eradication of Barrett’s esophagus with radio frequency ablation – results from a BETRNet consortium. Gastroenterology 2012; 142: 73
  PubMedGoogle Scholar
• 6 DeMeester SR, Awais O, Bergman JJ et al. Initial human experience with a novel through-the-scope cryoballoon device for mucosal ablation. Gastroenterology 2012; 142: 1038
  CrossrefPubMedGoogle Scholar
• 7 Grisan E, Veronese E, Diamantis G et al. Computer aided diagnosis of Barrett’s esophagus using confocal laser endomicroscopy: preliminary data. Gastrointest Endosc 2012; 75: AB126
  PubMedGoogle Scholar
• 8 Borgulya M, Kurz CM, Knoll T et al. Diagnosis of early Barrett’s neoplasia and esophageal squamous cell neoplasia by electrical bio-impedance spectroscopy in human tissue. Gastrointest Endosc 2012; 75: AB127
  PubMedGoogle Scholar
• 9 Canto MI, Anandasabapathy A, Brugge WR et al. In vivo endoscope-based confocal laser endomicroscopy (eCLE) improves detection of unlocalized Barrett’s esophagus-related neoplasia over high resolution white light endoscopy: an international multicenter randomized controlled trial. Gastrointest Endosc 2012; 75: AB174
  PubMedGoogle Scholar
• 10 Wallace MB, Crook J, Saunders MD et al. Multicenter, randomized controlled trial of confocal laser endomicroscopy assessment of residual neoplasia after mucosal ablation or resection of gastrointestinal neoplasia in Barrett’s esophagus (clean margin trial). Gastrointest Endosc 2012; 75: AB174
  PubMedGoogle Scholar
• 11 Verbeek RE, Leenders MB, van Oijen MG et al. surveillance is associated with a lower tumor stage and increased survival in Barrett’s esophagus patients diagnosed with esophageal adenocarcinoma. Gastrointest Endosc 2012; 75: AB175
  PubMedGoogle Scholar
• 12 Gaddam S, Singh M, Balasubramanian G et al. Decreasing rates of esophageal adenocarcinoma (EAC) in patients with persistent non dysplastic Barrett’s esophagus (NDBE): results from a large multicenter cohort. Gastroenterology 2012; 142: 166
  PubMedGoogle Scholar
• 13 Pacha A, Rygiel AM, Westra W et al. Biomarker assay detects Barrett progressors: a phase iv five year prospective follow up study. Gastroenterology 2012; 142: 72
  PubMedGoogle Scholar
• 14 Colavita PD, Belyansky I, Walters A et al. nationwide inpatient sample: have antireflux procedures undergone regionalization?. Gastroenterology 2012; 142: 1041
  PubMedGoogle Scholar
• 15 Bello BL, Zoccali M, Gullo R et al. Gastroesophageal reflux disease (GERD) and antireflux surgery (ARS). What is the proper preoperative workup?. Gastroenterology 2012; 142: 1033
  PubMedGoogle Scholar
• 16 Babaei A, Naini SR, Hogan WJ et al. Efficacy of a novel “UES assist device” in management of supraesophageal complications of reflux disease: the results of a limited clinical trial. Gastroenterology 2012; 142: 102
  PubMedGoogle Scholar
• 17 Schoepfer A, Safroneeva E, Bussmann C et al. Fixed rings and strictures in eosinophilic esophagitis develop due to continuing inflammation over time. Gastroenterology 2012; 142: 180
  CrossrefPubMedGoogle Scholar
• 18 Gonsalves N, Schroeder H, Doerfler B et al. A unique gene expression profile may predict responsiveness to dietary elimination with six food elimination diet in adults with eosinophilic esophagitis. Gastroenterology 2012; 142: 181
  PubMedGoogle Scholar
• 19 Dellon ES, Sheikh A, Speck O et al. Nebulized/swallowed vs viscous/swallowed budesonide for treatment of eosinophilic esophagitis: results from a randomized, open-label, clinical trial. Gastroenterology 2012; 142: 180
  CrossrefPubMedGoogle Scholar
• 20 Dellon ES, Sheikh A, Whitlow A et al. Mucosal contact time determines histologic effectiveness of oral budesonide preparations in eosinophilic esophagitis: a randomized trial using scintigraphy. Gastroenterology 2012; 142: 180
  CrossrefPubMedGoogle Scholar